NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China

Reuters

09/04

NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China

NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and Ocumension Therapeutics. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564328513"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564328513\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564328513?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564328513","market":"nz","top_or_hot":-1,"title":"NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and <a href=\"https://laohu8.com/S/OCUTF\">Ocumension Therapeutics</a>. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 13:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and <a href=\"https://laohu8.com/S/OCUTF\">Ocumension Therapeutics</a>. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"納斯達克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL1L12kY:1","article_id":"2564328513","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564328513","pubTimestamp":1756963830,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and Ocumension Therapeutics. The company has stated that the trial results have met the requirements for New Drug Application  submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK1191":"制药","01477":"欧康维视生物-B","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK1574":"生物医药B类股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"NicOx SA宣布NCX 470在美国和中国成功进行3期试验并即将提交NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":0.9,"NDAQ":0.9},"content_text":"NicOx SA Announces Successful Phase 3 Trials and Upcoming NDA Submissions for NCX 470 in U.S. and China\n    \n\n        NicOx SA, a biotech company specializing in ophthalmology, has announced the completion of the second pivotal Phase 3 clinical trial, Denali, for its lead product candidate, NCX 470, in the U.S. and China. This development follows the global licensing of NCX 470 to Kowa and Ocumension Therapeutics. The company has stated that the trial results have met the requirements for New Drug Application (NDA) submissions in both the U.S. and China. An NDA filing in the United States is expected in the first half of 2026, with the submission in China to follow subsequently. The company anticipates that these submissions will lead to milestone payments in 2026 and 2027, with recurrent revenue from royalties on net sales expected from 2027. The costs associated with the NDA submissions will be covered by NicOx's partners, Kowa and Ocumension.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001126201-en) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}